Novo Nordisk announced a major investment of $4.1 billion to construct a new manufacturing plant in Clayton, North Carolina. This strategic move aims to address the high demand and supply shortages of its blockbuster drugs, Wegovy and Ozempic, as well as other injectable therapies.